ScoreWhy is Mangalam Drugs and Organics Ltd ?
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -8.78% and Operating profit at -182.89% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 7.88 times
2
The company has declared Negative results for the last 4 consecutive quarters
- PBT LESS OI(Q) At Rs -9.95 cr has Fallen at -74.2% (vs previous 4Q average)
- PAT(Q) At Rs -9.84 cr has Fallen at -98.8% (vs previous 4Q average)
- NET SALES(Q) At Rs 58.49 cr has Fallen at -12.9% (vs previous 4Q average)
3
Risky - Negative Operating Profits
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -66.57%, its profits have fallen by -396.6%
4
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -14.66% over the previous quarter and currently hold 35.64% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
5
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -66.57% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Mangalam Drugs for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Mangalam Drugs
-66.66%
-1.23
54.36%
Sensex
6.66%
0.57
11.66%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-8.78%
EBIT Growth (5y)
-182.89%
EBIT to Interest (avg)
0.24
Debt to EBITDA (avg)
3.75
Net Debt to Equity (avg)
0.72
Sales to Capital Employed (avg)
1.72
Tax Ratio
8.14%
Dividend Payout Ratio
0
Pledged Shares
7.09%
Institutional Holding
0.14%
ROCE (avg)
11.27%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
33
Price to Book Value
0.45
EV to EBIT
-8.82
EV to EBITDA
104.72
EV to Capital Employed
0.68
EV to Sales
0.62
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2.85%
ROE (Latest)
-15.52%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-16What is not working for the Company
PBT LESS OI(Q)
At Rs -9.95 cr has Fallen at -74.2% (vs previous 4Q average
PAT(Q)
At Rs -9.84 cr has Fallen at -98.8% (vs previous 4Q average
NET SALES(Q)
At Rs 58.49 cr has Fallen at -12.9% (vs previous 4Q average
Loading Valuation Snapshot...
Here's what is not working for Mangalam Drugs
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -9.95 cr has Fallen at -74.2% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs -5.71 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs -9.84 cr has Fallen at -98.8% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs -4.95 CrMOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Net Sales - Quarterly
At Rs 58.49 cr has Fallen at -12.9% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 67.16 CrMOJO Watch
Near term sales trend is very negative
Net Sales (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
